Cargando…
Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly neede...
Autores principales: | Castella, Barbara, Melaccio, Assunta, Foglietta, Myriam, Riganti, Chiara, Massaia, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232124/ https://www.ncbi.nlm.nih.gov/pubmed/30460198 http://dx.doi.org/10.3389/fonc.2018.00508 |
Ejemplares similares
-
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
por: Castella, Barbara, et al.
Publicado: (2018) -
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status
por: Giannotta, Claudia, et al.
Publicado: (2022) -
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
por: Castella, Barbara, et al.
Publicado: (2015) -
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells
por: Castella, Barbara, et al.
Publicado: (2017) -
Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice
por: Matas-Céspedes, Alba, et al.
Publicado: (2023)